Feedback

Cinobufagin alleviates lipopolysaccharide-induced acute lung injury by regulating autophagy through activation of the p53/mTOR pathway

Affiliation
Department of Critical Care Medicine ,Medical Center of Anesthesiology and Pain ,The First Affiliated Hospital of Nanchang University ,Nanchang ,China
Wang, Cheng;
Affiliation
Department of Gastrointestinal Surgery ,Heji Hospital Affiliated to Changzhi Medical College ,Changzhi ,China
Mei, Xianghuang;
Affiliation
Department of Ophthalmology ,Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine ,Nanchang ,China
Wu, Yanrong;
Affiliation
Department of Critical Care Medicine ,Medical Center of Anesthesiology and Pain ,The First Affiliated Hospital of Nanchang University ,Nanchang ,China
Yang, Yuting;
Affiliation
Department of Critical Care Medicine ,Medical Center of Anesthesiology and Pain ,The First Affiliated Hospital of Nanchang University ,Nanchang ,China
Zeng, Zhenguo

Acute lung injury (ALI) is a severe clinical disorder characterized by dysregulated inflammatory responses, leading to high rates of morbidity and mortality. Cinobufagin, a primary component isolated from cinobufotalin, exerts strong anticancer effects. However, there are few reports on its role in ALI, and it is unclear whether cinobufagin affects lipopolysaccharide (LPS)-induced ALI. Therefore, the present study aimed to investigate the effect of cinobufagin on LPS-induced ALI and to assess its potential mechanism of action. The results showed that cinobufagin alleviated lung histopathological changes and protected the permeability of lung tissues in LPS-induced ALI. In addition, cinobufagin effectively suppressed inflammatory responses through the induction of autophagy in LPS-induced ALI cells and in a mouse model. Moreover, cinobufagin enhanced autophagy through the p53/mTOR pathway in LPS-induced ALI. Herein, it was reported for the first time that cinobufagin inhibited the inflammatory response of LPS-induced ALI, which laid the foundation for further understanding and development of cinobufagin as a potential new drug for ALI.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Wang, Mei, Wu, Yang and Zeng.

Use and reproduction: